Pune, India — Maharashtra’s Food and Drug Administration (FDA) has cancelled the drug sale licence of Cipla Pharma & Life Sciences Ltd.’s C&F facility in Wadki, Pune, following findings related to the storage, record-keeping and distribution of Reactin Plus Tablets.